psalexa
logo

Sarcopenia Therapeutics - Pipeline Analysis 2018

Sarcopenia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: February 2018
Report Code: LS11414
Available Format:
Pages: 81

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Sarcopenia is a disease characterized by degenerative loss of skeletal muscle mass, quality, and strength associated with aging which eventually weakens a person, making it difficult for a patient to walk or move around easily.

 

SARCOPENIA THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2018)

SARCOPENIA-THERAPEUTICS-DRUG-CANDIDATES

Further, the risk factors for the development of sarcopenia are sedentary lifestyle, malnutrition, and aging. Consumption of high amounts of acid producing foods, such as grains and processed foods, and eating very few vegetables and fruits decreases the development of muscle mass. Muscle loss occurs due to decreased protein synthesis which is related to the reduction in anabolic factors and an increase in proteolysis. Muscle mass development is based on certain stimulating factors such as insulin, ghrelin, testosterone, IGF-1 and Vitamin D and the inhibitor factors, such as myostatin which act as an autocrine factor.

The symptoms of the disease are decreased muscle strength, poor mobility, frailty, weak bones (osteoporosis), falls and fractures, diabetes, and loss of physical function and independence. Sarcopenia can be diagnosed by a Dual-energy X-ray Absorptiometry (DXA) and also through a walking speed test.

Currently, there are no medications approved by the USFDA for the treatment of sarcopenia. According to the data published in the “Journal of Diabetes and Metabolic disorders’” in May 2017, the overall prevalence of sarcopenia is 10%, globally. The prevalence was higher among non- Asian population as compared to the Asian population, across both genders. Technological advancements, increased funding from government bodies and private sector are the factors driving the growth of sarcopenia therapeutics pipeline.

Pipeline Analysis

The sarcopenia therapeutics pipeline comprises of 13 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of sarcopenia include Novartis AG, Biophytis SAS, Vibe Pharmaceuticals LLC.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry